RT Journal Article
T1 Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment.
A1 Pinto-Medel, Maria Jesus
A1 Oliver-Martos, Begoña
A1 Urbaneja-Romero, Patricia
A1 Hurtado-Guerrero, Isaac
A1 Ortega-Pinazo, Jesus
A1 Serrano-Castro, Pedro
A1 Fernandez, Oscar
A1 Leyva, Laura
K1 Multiple Sclerosis
K1 Multivariate Analysis
K1 ROC Curve
K1 Reference Standards
AB The alteration of DNA methylation patterns are a key component of disease onset and/or progression. Our objective was to evaluate the differences in Long Interspersed Nuclear Element-1 (LINE-1) methylation levels, as a surrogate marker of global DNA methylation, between multiple sclerosis (MS) patients and healthy controls. In addition, we assessed the association of LINE-1 methylation with clinical disease activity in patients treated with IFNbeta (IFNβ). We found that individuals with high levels of LINE-1 methylation showed 6-fold increased risk of suffering MS. Additionally, treated MS patients who bear high LINE-1 methylation levels had an 11-fold increased risk of clinical activity. Moreover, a negative correlation between treatment duration and percentage of LINE-1 methylation, that was statistically significant exclusively in the group of patients without clinical activity, was observed. Our data suggest that in MS patients, a slight global DNA hypermethylation occurs that may be related to the pathophysiology of the disease. In addition, global DNA methylation levels could play a role as a biomarker for the differential clinical response to IFNβ.
PB Nature Publishing Group
YR 2017
FD 2017-08-18
LK http://hdl.handle.net/10668/11520
UL http://hdl.handle.net/10668/11520
LA en
NO Pinto-Medel MJ, Oliver-Martos B, Urbaneja-Romero P, Hurtado-Guerrero I, Ortega-Pinazo J, Serrano-Castro P, et al. Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment. Sci Rep. 2017 Aug 18;7(1):8727
NO This work was supported by grants from the Consejeria de Salud de la Junta de Andalucia to MJPM (SAS 111228 and PI-0214-2014) and from the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CTS7670/11) cofinanced by Fondo Europeo de Desarrollo Regional (FEDER) to LL.
DS RISalud
RD Apr 7, 2025